Leukemia, Myeloid, Acute Clinical Trial
Official title:
Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
This is a phase I study designed to test the safety of oral clofarabine when given as consolidation therapy to older patients with AML in remission.
Status | Completed |
Enrollment | 25 |
Est. completion date | November 2014 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of Acute Myeloid Leukemia according to WHO criteria - Age = 60 years at enrollment - Patients must be in complete remission by bone marrow examination, within 30 days of enrollment, following treatment with a cytotoxic induction chemotherapy regimen (such as 7+3) - Complete remission must be confirmed by bone marrow biopsy - If one cycle of consolidation was administered, then patient may be within 60 days of the confirmation of complete remission by bone marrow biopsy - Minimum platelet count of 100,000 - Patients may have received "low-intensity" therapy (i.e. decitabine, lenalidomide, etc) prior to traditional induction chemotherapy. - Patients may have received 1 cycle of cytarabine-based consolidation therapy. - Patients must have an ECOG performance status of 0-2 at the beginning of consolidation therapy. - Have adequate renal and hepatic functions as indicated by the following laboratory values: - Serum creatinine = 1.0 mg/dL; if serum creatinine >1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be >60 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2) = 186 x (Serum Creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is female) x (1.212 if patient is black) - Serum total bilirubin = 1.5 mg/dL × upper limit of normal (ULN) except for unconjugated hyperbilirubinemia secondary Gilbert's syndrome - Aspartate transaminase (AST)/alanine transaminase (ALT) = 2.5 × ULN - Alkaline phosphatase = 2.5 × ULN - Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide signed valid written informed consent or when appropriate, have an appointed legally authorized representative who is capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide signed valid written informed consent for the benefit of the patient. - Male and female patients who are of child bearing potential must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment. - Patients MAY have received prior therapy with purine analogs (such as fludarabine and cladribine). Exclusion Criteria: - Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol. - The diagnosis of AML-M3 (acute promyelocytic leukemia) characterized by translocations involving the retinoic acid receptor-alpha (RAR-alpha) gene. - Use of investigational agents within 2 weeks or any anticancer therapy within 2 weeks before study entry. The patient must have recovered from all acute toxicities from any previous therapy. - Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment. - Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). - Have currently active gastrointestinal disease, or prior surgery that may affect the ability of the patient to absorb oral clofarabine. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Washington University | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose (MTD) and dose limiting toxicity (DLT) | DLT - 1st cycle (28 days), MTD - completion of 1st cycle by all patients in all cohorts | Yes | |
Secondary | Adverse events by grade and attribution | Start of treatment through 30 days post-last dose | Yes | |
Secondary | Disease-free survival | Every 6 months for 3 years | No | |
Secondary | Overall survival | Every 6 months for 3 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05319587 -
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04090736 -
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
|
Phase 3 | |
Completed |
NCT01617226 -
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
|
Phase 2 | |
Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
Terminated |
NCT00957580 -
Trial of Pimasertib in Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00640796 -
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
|
Phase 1 | |
Completed |
NCT00458250 -
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
|
Phase 1 | |
Active, not recruiting |
NCT05424380 -
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
|
Phase 1 | |
Completed |
NCT01690624 -
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse
|
Phase 1 | |
Recruiting |
NCT05471700 -
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05016063 -
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Early Phase 1 | |
Not yet recruiting |
NCT04450784 -
ObServatory Children Acute RElated Therapy Leukemia
|
||
Recruiting |
NCT04265963 -
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT04968860 -
Oral Health Condition and Quality of Life in Children With Leukemia
|
||
Recruiting |
NCT03793517 -
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
|
Phase 2/Phase 3 | |
Terminated |
NCT02841540 -
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
|
Phase 1 | |
Recruiting |
NCT05453903 -
A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
|
Phase 1 | |
Completed |
NCT03720366 -
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
|
Phase 1 | |
Withdrawn |
NCT04230564 -
Acute Myeloid Leukemia Real World Treatment Patterns
|
||
Terminated |
NCT03761069 -
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
|
Phase 1 |